VS: Aanbevolen praktijken voor distributie van wetenschappelijke en medische publicaties met risico-informatie voor goedgekeurde geneesmiddelen op recept en biologische producten

This draft guidance describes the Food and Drug Administration’s current thinking on recommended practices for drug manufacturers and their representatives to follow if they choose to distribute to health care professionals or health care entities scientific or medical journal articles that discuss new risk information for approved prescription drugs marketed in the United States.
The recommendations in this draft guidance are intended to address issues specific to the distribution of new information about risks associated with a drug that further characterizes risks identified in the approved labeling of drugs intended for human and animal use (FDA Daily Digest Bulletin, 6 juni 2014).
Klik hier om de richtlijnen voor de industrie te downloaden (95 kB).

Dit bericht is ook opgenomen in ons maandelijkse overzicht, de NVC Members-only Update. Heeft u vragen, neem dan contact met ons op via e-mail of bel: +31-(0)182-512411.